Exablate Blood-Brain Barrier Disruption With Carboplatin for the Treatment of rGBM

Summary

The purpose of this study is to evaluate the safety and feasibility of the Exablate Model 4000 Type 2 system when used as a tool to open the blood-brain-barrier (BBB) in subjects with recurrent glioblastoma (rGBM) undergoing carboplatin monotherapy.

Timeline

Start

2020-10-13

Primary completion

2023-11-30

Completion

2023-12-31

Drugs

Indications